[Federal Register: September 15, 2005 (Volume 70, Number 178)]
[Notices]
[Page 54561]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15se05-44]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Pediatric Oncology Subcommittee of the Oncologic
Drugs Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on October 20, 2005, from 8
a.m. to 5 p.m.
Location: Food and Drug Administration, Center for Drug Evaluation
and Research (CDER), Advisory Committee Conference Room, rm. 1066, 5630
Fishers Lane, Rockville, MD.
Contact Person: Victoria Ferretti-Aceto, Center for Drug Evaluation
and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane,
(for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD
20857, 301-827-7001, FAX: 301-827-6776, e-mail: ferrettiv@cder.fda.gov,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 3014512542. Please call the
Information Line for up-to-date information on this meeting.
Agenda: The subcommittee will do the following: (1) Present the
structure and function of the Office of Oncology Drug Products in CDER,
(2) discuss issues involved with the conduct of certain pediatric
postmarketing studies for products approved for oncologic indications,
(3) review status of studies for specific off-patent drugs for
pediatric oncology, and (4) consider other off-patent oncology drugs
for which pediatric studies are needed, as mandated by the Best
Pharmaceuticals for Children Act. When available, background materials
for this meeting will be posted 1 business day before the meeting on
FDA's Web site at http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/ohrms/dockets/ac/acmenu.htm.
(Click on the year 2005 and scroll down to Oncologic Drugs Advisory
Committee; Pediatric Subcommittee.)
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the subcommittee.
Written submissions may be made to the contact person by October 13,
2005. Oral presentations from the public will be scheduled between
approximately 11:45 a.m. and 12:15 p.m., and between approximately 3
p.m. and 3:30 p.m. Time allotted for each presentation may be limited.
Those desiring to make formal oral presentations should notify the
contact person before October 13, 2005, and submit a brief statement of
the general nature of the evidence or arguments they wish to present,
the names and addresses of proposed participants, and an indication of
the approximate time requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Victoria Ferretti-
Aceto at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: September 6, 2005.
Scott Gottlieb,
Deputy Commissioner for Policy.
[FR Doc. 05-18330 Filed 9-14-05; 8:45 am]
BILLING CODE 4160-01-S